Avenzo Therapeutics

We are pleased to announce the appointment of Scott Lipman, M.B.A., as our new Chief Financial Officer.   In his expanded role as CFO, Scott will lead our finance & accounting functions while continuing to serve as Chief Business Officer, overseeing our business development efforts, as we advance our clinical-stage #oncology programs and prepare for the company’s next stage of growth.   Read the full press release here: https://bit.ly/3LLt5jo

We’re proud to announce that the U.S. Food and Drug Administration has granted Fast Track designation to our potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate for the treatment of EGFR-mutated TKI-pretreated non-small cell #lungcancer (NSCLC). This important milestone reaffirms our commitment to developing next-generation oncology therapies that help make a difference in the lives of patients. Learn more: https://bit.ly/3JTEZac #oncology #fasttrackdesignation

We’re excited to announce the acceptance of two abstracts for poster presentations at the upcoming 2025 San Antonio Breast Cancer Symposium in December, hosted by UT Health San Antonio and the American Association for Cancer Research. We look forward to sharing preliminary safety and efficacy results from the Phase 1 portion of our ongoing Phase 1/2 clinical study of our potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor. We’ll also highlight the Phase 1/2 study design of our potential best-in-class cyclin-dependent kinase 4 (CDK4) selective inhibitor in patients with advanced #solidtumors. http://bit.ly/3Wxgpi7 #SABCS25

We’re excited to highlight our potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (BsADC) during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Therapeutics, hosted by the American Association for Cancer Research.    We look forward to sharing details from our Phase 1/2 study evaluating our BsADC in patients with locally advanced or metastatic #solidtumors, and to connecting with fellow industry leaders to advance targeted therapies in #oncology.  #Targets25

Today, we announced the initiation of the Phase 1/2 study of our potential best-in-class Nectin4/TROP2 bispecific #ADC in patients with advanced #solidtumors, including urothelial cancer. The study marks our fourth clinical stage program at Avenzo, reflecting our continued commitment to advancing next-gen #oncology therapies for patients. Learn more here: http://bit.ly/4mLJIrX

Today marks another important step in our growth as we announce the closing of our $60M Series B financing.     Proceeds will support the advancement of our portfolio of potential best-in-class #oncology drug candidates as we build on the strong progress we've made this year. We are grateful to our new and existing investors for their continued partnership and confidence in our mission to develop next-generation oncology therapies for cancers with high unmet medical needs.     Read the full press release here: http://bit.ly/4pBdnXr

We’re excited to share that we have received Investigational New Drug Application (IND) clearance for our potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (#ADC) – marking our third IND to clear this year. We’ve also exercised our exclusive option for this asset from VelaVigo, securing global (excluding Greater China) development, manufacturing, and commercialization rights.   Stay tuned for more information on our plans to initiate a Ph 1/2 clinical study later this year, assessing the safety, tolerability, and preliminary clinical activity of this asset as a single agent and in combination therapy in patients with advanced #solidtumors. Learn more: https://bit.ly/3JJQEIg

We’re happy to share that the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating our potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate in patients with advanced #solidtumors.    By targeting EGFR and HER3, this investigational bispecific antibody-drug candidate has the potential to improve tumor cell selectivity and maximize therapeutic impact across multiple solid tumor types.   We look forward to studying its potential as we continue our mission of developing next-generation #oncology therapies. Read more in the press release: http://bit.ly/409vlFn

We’re thrilled to welcome Hani Maroki Ghazarian, the newest member of #TeamAvenzo! His background in clinical pharmacology and pharmacometrics along with his extensive hands-on experience supporting oncology clinical trials will help advance our pipeline of potentially best-in-class #oncology therapies to fight cancers with high unmet medical needs. Welcome, Hani!

We are excited to welcome Mara Villalpando as our new senior director, Pharmacovigilance! Her knowledge of and expertise in drug safety will be beneficial as we continue our focus on transforming #cancer treatments and delivering better medicines to patients. #TeamAvenzo